Ex-Meditech CEO to head WA firm Acuron
Monday, 29 November, 2004
Three months after being forced to step down as CEO of Melbourne biotech Meditech (ASX:MTR) after a shareholder stoush, expat South African Chris Carter has been appointed CEO of Western Australian minerals-explorer-turned-biotech Acuron (ASX:AVP).
Acuron's two wholly owned subsidiaries, Vacutex and Pro-Tex, manufacture and distribute a range of advanced wound care products. The company's flagship product -- capillary action dressing Vacutex -- has been approved by the TGA and the UK's National Health Scheme, and is also distributed in the Middle East and parts of South-East Asia. Acuron is in the process of submitting for approval from the US Food and Drug Administration (FDA).
Carter will take over from George Cameron-Dow as Acuron's managing director, and from Johann Fourie as CEO of both Vacutex and Pro-Tex. Both Cameron-Dow and Fourie will move to non-executive roles.
"We are very pleased to announce Chris's appointment as we accelerate the global roll-out of Acuron's advanced wound care product range." said Acuron chairman, Patrick O'Connor in a statement. "Chris has a strong track record in developing healthcare businesses and in securing the support of institutional investors."
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
